

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 01 INPADOC: New family current-awareness alert (SDI) available  
NEWS 4 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 5 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX  
NEWS 6 SEP 27 STANDARDS will no longer be available on STN  
NEWS 7 SEP 27 SWETSCAN will no longer be available on STN  
NEWS 8 OCT 28 KOREAPAT now available on STN  
NEWS 9 NOV 18 Current-awareness alerts, saved answer sets, and current  
search transcripts to be affected by CERAB, COMPUAB, ELCOM,  
and SOLIDSTATE reloads

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:33:54 ON 29 NOV 2004

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

1.26

1.26

FILE 'REGISTRY' ENTERED AT 13:37:20 ON 29 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8  
DICTIONARY FILE UPDATES: 28 NOV 2004 HIGHEST RN 790189-55-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10740245.str



chain nodes :  
20 21 22 23  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  
chain bonds :  
5-20 10-21 20-21 20-23 21-22  
ring bonds :  
1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-12 10-11 10-15 11-12 12-13  
13-16 14-15 14-19 15-16 16-17 17-18 18-19  
exact/norm bonds :  
1-2 1-5 2-3 3-4 4-5 5-20 20-21 21-22  
exact bonds :  
10-11 10-15 10-21 12-13 13-16 20-23  
normalized bonds :  
6-7 6-11 7-8 8-9 9-12 11-12 14-15 14-19 15-16 16-17 17-18 18-19  
isolated ring systems :  
containing 1 : 6 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:CLASS 21:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> D L1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1

SAMPLE SEARCH INITIATED 13:37:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 3 TO 163

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1

=> S L1 SSS FULL

FULL SEARCH INITIATED 13:37:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS


SEARCH TIME: 00.00.01

19 ANSWERS

L3 19 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10740245A.str



chain nodes :

20 21 22 23 25

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds :

3-25 5-20 10-21 20-21 20-23 21-22

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-12 10-11 10-15 11-12 12-13  
13-16 14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 5-20 20-21 21-22

exact bonds :

3-25 10-11 10-15 10-21 12-13 13-16 20-23

normalized bonds :

6-7 6-11 7-8 8-9 9-12 11-12 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems :

containing 1 : 6 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:CLASS 21:CLASS 22:CLASS 23:CLASS 25:CLASS

L4 STRUCTURE UPLOADED

=> D L4

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L4

SAMPLE SEARCH INITIATED 13:39:33 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 1 TO 80  
PROJECTED ANSWERS: 1 TO 80

L5 1 SEA SSS SAM L4

=> S L4 SSS FULL

FULL SEARCH INITIATED 13:39:39 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 8 TO ITERATE

100.0% PROCESSED 8 ITERATIONS  
SEARCH TIME: 00.00.01

8 ANSWERS

L6 8 SEA SSS FUL L4

=> D HIS

(FILE 'HOME' ENTERED AT 13:33:54 ON 29 NOV 2004)

FILE 'REGISTRY' ENTERED AT 13:37:20 ON 29 NOV 2004

L1 STRUCTURE UPLOADED  
L2 3 S L1  
L3 19 S L1 SSS FULL  
L4 STRUCTURE UPLOADED  
L5 1 S L4  
L6 8 S L4 SSS FULL

10740245 .trn

11/29/2004

=&gt; FIL CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

311.68

312.94

FILE 'CAPLUS' ENTERED AT 13:39:51 ON 29 NOV 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2004 VOL 141 ISS 23

FILE LAST UPDATED: 28 Nov 2004 (20041128/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=&gt; S L3

L7

2 L3

=&gt; S L6

L8

1 L6

=&gt; d l7. ibib abs hitstr tot

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:550747 CAPLUS

DOCUMENT NUMBER: 141:89081

TITLE: Preparation of 9H-xanthene-9-carboxylic acid (oxazol-2-yl)amide derivatives as mGluR1 enhancers

INVENTOR(S): Hawyler, Joerg; Knoeflach, Frederic; Vieira, Eric; Wichmann, Juergen

PATENT ASSIGNEE(S): Switz.

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.    | KIND | DATE     | APPLICATION NO. | DATE     |
|---------------|------|----------|-----------------|----------|
| US 2004132792 | A1   | 20040708 | US 2003-740245  | 20031218 |
| WO 2004056814 | A1   | 20040708 | WO 2003-EP14395 | 20031217 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,  
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:


EP 2002-28747

A 20021223

OTHER SOURCE(S):

MARPAT 141:89081

GI



AB The title compds. (I; wherein one of R1 and R2 is CF3, and the other is H; R3 and R3' are each independently H or halogen) or pharmaceutically acceptable salt thereof are prepared These compds. are useful as mGluR1 enhancers in the treatment and prevention of neurol. disorders and diseases, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's chorea, and dementia. Thus, to a solution of 150 mg (0.99 mmol, 1.0 equivalent) (4-trifluoromethyloxazol-2-yl)amine > and 6 mg (0.05 mmol, 0.05 equivalent) N,N-bis(methylamino)pyridine in 2 mL dry pyridine was added a solution of 245 mg (0.99 mmol) 9-xanthene-carbonyl chloride in 2 mL CH2Cl2 dropwise at 0° and the mixture was stirred 1 h at 0° and then at room temperature overnight to give, after workup and recrystn. from EtOAc/hexane 250 mg (0.66 mmol, 66%) 9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide as white crystals.

IT 714971-87-6P, 9H-Xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-88-7P, 9H-Xanthene-9-carboxylic acid N-(5-trifluoromethyloxazol-2-yl)amide 714971-89-8P, 2-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-90-1P, 2-Fluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethyloxazol-2-yl)amide 714971-91-2P, 3-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-92-3P, 4-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-93-4P, 4-Fluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethyloxazol-2-yl)amide 714971-94-5P, 2,7-Difluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-95-6P, 2,7-Difluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethyloxazol-2-yl)amide 714971-96-7P, 3,6-Difluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-97-8P, 3,6-Difluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethyloxazol-2-yl)amide 714971-98-9P, 2-Chloro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-99-0P, 4-Chloro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714972-04-0P,


3-Fluoro-9H-xanthene-9-carboxylic acid N-(5-trifluoromethyloxazol-2-yl)amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 9H-xanthene-9-carboxylic acid (oxazol-2-yl)amide derivs. as mGluR1 enhancers for treatment and prevention of neurol. disorders and diseases)


RN 714971-87-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)



RN 714971-88-7 CAPLUS


CN 9H-Xanthene-9-carboxamide, N-[5-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)



RN 714971-89-8 CAPLUS


CN 9H-Xanthene-9-carboxamide, 2-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)






RN 714971-90-1 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2-fluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-(9CI) (CA INDEX NAME)



RN 714971-91-2 CAPLUS


CN 9H-Xanthene-9-carboxamide, 3-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-(9CI) (CA INDEX NAME)



RN 714971-92-3 CAPLUS


11/29/2004

CN 9H-Xanthene-9-carboxamide, 4-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)




RN 714971-93-4 CAPLUS

CN 9H-Xanthene-9-carboxamide, 4-fluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)




RN 714971-94-5 CAPLUS


CN 9H-Xanthene-9-carboxamide, 2,7-difluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)



RN 714971-95-6 CAPLUS


CN 9H-Xanthene-9-carboxamide, 2,7-difluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)

RN 714971-96-7 CAPLUS

CN 9H-Xanthene-9-carboxamide, 3,6-difluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)


RN 714971-97-8 CAPLUS

CN 9H-Xanthene-9-carboxamide, 3,6-difluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)



RN 714971-98-9 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2-chloro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)



RN 714971-99-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, 4-chloro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)

11/29/2004

DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,  
MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6462198 B1 20021008 US 2000-545622 20000410  
CA 2367368 AA 20001026 CA 2000-2367368 20000419  
EP 1171423 A1 20020116 EP 2000-929386 20000419

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

BR 2000009885 A 20020122 BR 2000-9885 20000419  
TR 200103010 T2 20020521 TR 2001-200103010 20000419  
JP 2002542229 T2 20021210 JP 2000-612262 20000419  
NZ 514487 A 20040130 NZ 2000-514487 20000419  
ZA 2001007837 A 20021223 ZA 2001-7837 20010921  
NO 2001005064 A 20011018 NO 2001-5064 20011018  
HR 2001000761 A1 20021231 HR 2001-761 20011019  
US 2002091150 A1 20020711 US 2001-8827 20011210

US 6596743 B2 20030722  
US 6803381 B1 20041012 US 2003-438361 20030514


PRIORITY APPLN. INFO.:

EP 1999-107843 A 19990420  
US 2000-545622 A3 20000410  
WO 2000-EP3556 W 20000419  
US 2001-8827 A3 20011210


OTHER SOURCE(S):

MARPAT 133:321633





GI



I




II




AB The title compds. I (R1 = H, lower alkyl; R2, R3 = independently H, alkyl, alkoxy, halo or CF<sub>3</sub>; X = O, S or two hydrogen atoms not forming a bridge; A1, A2 = independently constitute benzo fusion or a fused 6-membered heterocycle containing 1 or 2 nitrogen atoms; B = R<sub>4</sub>YC(:Z) {Y = O, S or bond; Z = O or S; R<sub>4</sub> = alkyl, alkenyl, alkynyl, benzyl, alkylpyridinyl, etc.}, or B = Q1, Q2, Q3, Q4 {R5 and R6 = H, alkyl, alkoxy, cyclohexyl,

11/29/2004



RN 714972-04-0 CAPLUS  
 CN 9H-Xanthene-9-carboxamide, 3-fluoro-N-[5-(trifluoromethyl)-2-oxazolyl]-(9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN  
 ACCESSION NUMBER: 2000:756670 CAPLUS  
 DOCUMENT NUMBER: 133:321633  
 TITLE: Preparation of carbamic acid derivatives and evaluation of their use as metabotropic glutamate receptor ligands  
 INVENTOR(S): Bleicher, Konrad; Mutel, Vincent; Vieira, Eric;  
 PATENT ASSIGNEE(S): Wichmann, Jürgen; Woltering, Thomas Johannes  
 SOURCE: F. Hoffmann-La Roche A.-G., Switz.  
 PCT Int. Appl., 48 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| ✓ WO 2000063166  | A1   | 20001026 | WO 2000-EP3556  | 20000419 |
| W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, |      |          |                 |          |

11/29/2004

alkylcyclohexyl or ~~CF<sub>3</sub>~~ with at least one R<sub>5</sub> or R<sub>6</sub> = H}} and their pharmaceutically acceptable salts and methods of preparation are disclosed. Thus, II was obtained in 83% yield by reaction of 1-butanol with diphenylacetyl isocyanate. Compds. of the invention demonstrated both agonistic (IC<sub>50</sub> = 0.14-0.22  $\mu$ M) and antagonistic (IC<sub>50</sub> = 1.38-6.31  $\mu$ M) behavior toward group I mGlu receptors. As metabotropic glutamate receptor ligands, these compds. may be used in the control or prevention of acute and/or chronic neurol. disorders.

IT 302841-98-1P 302842-00-8P 302842-01-9P


302842-02-0P 302842-05-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn of carbamic acid derivs. as metabotropic glutamate receptor ligands)


RN 302841-98-1 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-2-oxazolyl- (9CI) (CA INDEX NAME)



RN 302842-00-8 CAPLUS


CN 9H-Xanthene-9-carboxamide, N-(5-ethyl-2-oxazolyl)- (9CI) (CA INDEX NAME)



RN 302842-01-9 CAPLUS


CN 9H-Xanthene-9-carboxamide, N-(5-methyl-2-oxazolyl)- (9CI) (CA INDEX NAME)

11/29/2004




RN 302842-02-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-(5-propyl-2-oxazolyl)- (9CI) (CA INDEX NAME)



RN 302842-05-3 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-(4-methyl-2-oxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT




=&gt; d l8 ibib abs hitstr tot

L8 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2004:550747 CAPLUS  
DOCUMENT NUMBER: 141:89081  
TITLE: Preparation of 9H-xanthene-9-carboxylic acid  
(oxazol-2-yl)amide derivatives as mGluR1 enhancers  
INVENTOR(S): Huwyler, Joerg; Knoflach, Frederic; Vieira, Eric;  
Wichmann, Juergen  
PATENT ASSIGNEE(S): Switz.  
SOURCE: U.S. Pat. Appl. Publ., 10 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE     |
|---|------|----------|-----------------|----------|
| US 2004132792   | A1   | 20040708 | US 2003-740245  | 20031218 |
| WO 2004056814   | A1   | 20040708 | WO 2003-EP14395 | 20031217 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU |      |          |                 |          |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |          |

PRIORITY APPLN. INFO.: EP 2002-28747 A 20021223  
OTHER SOURCE(S): MARPAT 141:89081  
GI



AB The title compds. (I; wherein one of R1 and R2 is CF3, and the other is H; R3 and R3' are each independently H or halogen) or pharmaceutically acceptable salt thereof are prepared These compds. are useful as mGluR1 enhancers in the treatment and prevention of neurol. disorders and diseases, such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's chorea, and dementia. Thus, to a solution of 150 mg (0.99 mmol, 1.0 equivalent) (4-trifluoromethyloxazol-2-

11/29/2004

yl)amine > and 6 mg (0.05 mmol, 0.05 equivalent) N,N-bis(methylamino)pyridine in 2 mL dry pyridine was added a solution of 245 mg (0.99 mmol) 9-xanthene-carbonyl chloride in 2 mL CH<sub>2</sub>Cl<sub>2</sub> dropwise at 0° and the mixture was stirred 1<sup>h</sup> at 0° and then at room temperature overnight to give, after workup and recrystn. from EtOAc/hexane 250 mg (0.66 mmol, 66%) 9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide as white crystals.


IT 714971-87-6P, 9H-Xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-89-8P, 2-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-91-2P, 3-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-92-3P, 4-Fluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-94-5P, 2,7-Difluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-96-7P, 3,6-Difluoro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-98-9P, 2-Chloro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide 714971-99-0P, 4-Chloro-9H-xanthene-9-carboxylic acid N-(4-trifluoromethyloxazol-2-yl)amide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 9H-xanthene-9-carboxylic acid (oxazol-2-yl)amide derivs. as mGluR1 enhancers for treatment and prevention of neurol. disorders and diseases)


RN 714971-87-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-89-8 CAPLUS


CN 9H-Xanthene-9-carboxamide, 2-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 714971-91-2 CAPLUS

CN 9H-Xanthene-9-carboxamide, 3-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)


RN 714971-92-3 CAPLUS

CN 9H-Xanthene-9-carboxamide, 4-fluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)

RN 714971-94-5 CAPLUS


CN 9H-Xanthene-9-carboxamide, 2,7-difluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)

RN 714971-96-7 CAPLUS


CN 9H-Xanthene-9-carboxamide, 3,6-difluoro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)

RN 714971-98-9 CAPLUS

CN 9H-Xanthene-9-carboxamide, 2-chloro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)



RN 714971-99-0 CAPLUS

CN 9H-Xanthene-9-carboxamide, 4-chloro-N-[4-(trifluoromethyl)-2-oxazolyl]-  
(9CI) (CA INDEX NAME)

=&gt; LOG Y

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE

ENTRY

15.16

SINCE FILE

ENTRY

-2.10

TOTAL

SESSION

328.10

TOTAL

SESSION

-2.10

STN INTERNATIONAL LOGOFF AT 13:40:58 ON 29 NOV 2004